Dustin Markle
Family Practice · Charlottesville, VANPI 1245529437
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Lilly USA, LLC at 35.5% of the total. Among family practice clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$593
- Pfizer$195
- AbbVie$176
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$76
- E.r. Squibb & Sons, L.L.C.$73
- Boehringer Ingelheim$72
- plus $486 from 18 others
What the payments were for
- Food & beverage$1,66199%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 43 | $593 |
| Pfizer | 14 | $195 |
| AbbVie | 11 | $176 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| Boehringer Ingelheim | 4 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| Amgen | 4 | $49 |
| Novo Nordisk | 3 | $42 |
| Novartis | 2 | $36 |
| Dexcom, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Boston Scientific | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Insulet Corporation | 1 | $21 |
| Abbott | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| GSK | 1 | $13 |
How this compares
$1,672 in reported general payments places this provider in the 95th percentile of 508 family practice providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 152 | $208,385 |
| MounjaroTirzepatide | 119 | $151,056 |
| EliquisApixaban | 98 | $85,542 |
| JardianceEmpagliflozin | 73 | $81,757 |
| LinzessLinaclotide | 63 | $41,371 |
| FarxigaDapagliflozin Propanediol | 34 | $39,762 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $29,588 |
| XareltoRivaroxaban | 36 | $27,497 |
| JanuviaSitagliptin Phosphate | 26 | $20,896 |
| MyrbetriqMirabegron | 35 | $19,197 |
| EntrestoSacubitril/Valsartan | 11 | $18,824 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $16,919 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $14,051 |
| Gabapentin | 540 | $9,680 |
| Dexlansoprazole DrDexlansoprazole | 35 | $9,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Levemir | $42 | $211,050164 claims |
| Lilly USA, LLCMounjaro | $593 | $151,056119 claims |
| PfizerEliquis | $195 | $85,54298 claims |
| Boehringer IngelheimJardiance | $72 | $81,75773 claims |
| AbbVieLinzess, Synthroid | $176 | $45,127108 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $19,19735 claims |
| NovartisEntresto | $36 | $18,82411 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $13 | $13,93024 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $51 | $6,74212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 508 family practice providers in Virginia.
Other family practice in Charlottesville
- Amanda LoucksCharlottesville$13K
- Ann KlecanCharlottesville$0
- Nicholas KiddCharlottesville$0
- Scott AdamsLynchburg$3K
- Gayatri VaddadiManassas$2K
- Meghna ChopraNewport News$408
- Yunzhou LiGlen Allen$119
- Daniel OlsonMidlothian$56
- Liqaa Al-KhozaieWoodbridge$36
- Jorge ZarateVirginia Beach$13
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.